DES and DCB with Similar Results in Femoropopliteal Artery Disease

Courtesy of Dr. Carlos Fava.

Nowadays, peripheral interventions are on the rise and the technological development of stents and balloons would help achieve better outcomes. Both drug-eluting stents (DES) and drug-coated balloons (DCB) have proved to be beneficial for femoropopliteal interventions, but the actual role of each of these technologies remains unclear.

DES de 2.0 mm para vasos muy pequeños: ¿Es viable?This prospective, randomized 1:1 study included 15 patients with intermittent claudication, femoropopliteal lesions, and Rutherford functional categories 2 to 5.

 

The devices used were the Zilver PTX platform stent (Cook Medical) and the In.Pact Admiral or In.Pact Pacific balloon (Medtronic Vascular).

 

Patient characteristics between groups were similar: the mean age was 69; 24% of patients had diabetes; most were classified as category 2-3; 20% had renal insufficiency; lesion length was 150 mm, and half the patients had total occlusions.


Read also: AHA 2018 | New-Generation DES Are Similar to Second-Generation DES Beyond Polymer.


In the DCB group, the bailout was 25%. Additionally, ≥30% residual lesions were also more frequent in that group.

 

Primary patency at 12 months was similar between groups (79.9% DEB, 79.3% DES; rate difference 0.6%; 95% confidence interval [CI]: 13% to 14.2%; p = 0.96) and there was a trend in favor of DES at 3 years. There were no differences as regards mortality or amputations. Improvement was similar for both groups.

 

Conclusion

Patency at 12 months, effectiveness, and safety of DES versus DCB plus bailout stenting in femoropopliteal interventions are comparable. There was a trend in favor of DES over DCB at 36 months.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients with Femoropopliteal Arterial Disease.

Reference: Yvonne Bausback et al. J Am Coll Cardiol 2019;73:667-79.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....